ID26555A - ANTIBODI FAP-α-SPESIFIK DENGAN PERBAIKAN KEMAMPUAN PRODUKSI - Google Patents
ANTIBODI FAP-α-SPESIFIK DENGAN PERBAIKAN KEMAMPUAN PRODUKSIInfo
- Publication number
- ID26555A ID26555A IDW20002198A ID20002198A ID26555A ID 26555 A ID26555 A ID 26555A ID W20002198 A IDW20002198 A ID W20002198A ID 20002198 A ID20002198 A ID 20002198A ID 26555 A ID26555 A ID 26555A
- Authority
- ID
- Indonesia
- Prior art keywords
- fap
- improvement
- specific antibody
- production ability
- ability
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98107925A EP0953639A1 (en) | 1998-04-30 | 1998-04-30 | FAPalpha-specific antibody with improved producibility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID26555A true ID26555A (id) | 2001-01-18 |
Family
ID=8231860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDW20002198A ID26555A (id) | 1998-04-30 | 1999-04-22 | ANTIBODI FAP-α-SPESIFIK DENGAN PERBAIKAN KEMAMPUAN PRODUKSI |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP0953639A1 (bg) |
| JP (1) | JP4421779B2 (bg) |
| KR (1) | KR100580936B1 (bg) |
| CN (1) | CN1303430A (bg) |
| AR (1) | AR016243A1 (bg) |
| AT (1) | ATE356873T1 (bg) |
| AU (1) | AU760305B2 (bg) |
| BG (1) | BG65034B1 (bg) |
| BR (1) | BR9910577A (bg) |
| CA (1) | CA2327586C (bg) |
| CO (1) | CO5050255A1 (bg) |
| DE (1) | DE69935516T2 (bg) |
| EA (1) | EA005401B1 (bg) |
| EE (1) | EE200000642A (bg) |
| ES (1) | ES2283114T3 (bg) |
| HU (1) | HUP0101501A3 (bg) |
| ID (1) | ID26555A (bg) |
| IL (1) | IL138701A0 (bg) |
| NO (1) | NO20005412L (bg) |
| NZ (1) | NZ508456A (bg) |
| PL (1) | PL358087A1 (bg) |
| SK (1) | SK16192000A3 (bg) |
| TR (1) | TR200003181T2 (bg) |
| UA (1) | UA73276C2 (bg) |
| WO (1) | WO1999057151A2 (bg) |
| YU (1) | YU66300A (bg) |
| ZA (1) | ZA200005506B (bg) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| WO2001068708A2 (en) * | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
| PE20021080A1 (es) * | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| AU2003278161A1 (en) * | 2002-06-21 | 2004-01-06 | Johns Hopkins University School Of Medicine | Membrane associated tumor endothelium markers |
| US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
| US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US7384744B2 (en) | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| PL378110A1 (pl) * | 2003-02-14 | 2006-03-06 | Biogen Idec Ma Inc. | Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek |
| WO2005110474A2 (en) | 2004-05-10 | 2005-11-24 | Macrogenics, Inc. | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| WO2007021841A2 (en) | 2005-08-10 | 2007-02-22 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| CA2631184A1 (en) * | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| CA2660592C (en) | 2006-05-26 | 2016-07-12 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| ES2599319T3 (es) | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Anticuerpos específicos de Fc RIIB y métodos de uso de éstos |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| CN104524567A (zh) | 2007-01-16 | 2015-04-22 | 阿布维公司 | 用于治疗银屑病的方法 |
| KR20100014674A (ko) | 2007-03-29 | 2010-02-10 | 아보트 러보러터리즈 | 결정성 항-사람 ｉｌ-12 항체 |
| KR101637533B1 (ko) * | 2007-08-20 | 2016-07-11 | 글락소 그룹 리미티드 | 제조 방법 |
| CN101896818B (zh) * | 2007-12-10 | 2016-01-20 | 霍夫曼-拉罗奇有限公司 | 作为癌症的标记物的Seprase |
| EP2071337A1 (en) * | 2007-12-10 | 2009-06-17 | F.Hoffmann-La Roche Ag | Seprase as a marker for cancer |
| CN101896817A (zh) * | 2007-12-10 | 2010-11-24 | 霍夫曼-拉罗奇有限公司 | 用于结直肠癌的标记物组 |
| RU2497545C2 (ru) | 2008-03-18 | 2013-11-10 | Эбботт Лэборетриз | Способ лечения псориаза (варианты) |
| JP5785490B2 (ja) | 2008-04-02 | 2015-09-30 | マクロジェニクス，インコーポレーテッド | Ｂｃｒ複合体特異的抗体およびその使用方法 |
| AU2009231991B2 (en) | 2008-04-02 | 2014-09-25 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
| AU2010291927A1 (en) | 2009-09-14 | 2012-04-12 | AbbVie Deutschland GmbH & Co. KG | Methods for treating psoriasis |
| AU2010303415B2 (en) | 2009-10-07 | 2015-02-19 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
| MX345232B (es) | 2010-03-04 | 2017-01-20 | Macrogenics Inc | Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y sus usos. |
| NZ703653A (en) * | 2010-08-13 | 2016-09-30 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| NZ714128A (en) | 2010-09-09 | 2017-10-27 | Pfizer | 4-1bb binding molecules |
| UA117294C2 (uk) | 2011-02-10 | 2018-07-10 | Рош Глікарт Аг | Імунокон'югат |
| AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| CN103267852B (zh) * | 2013-05-15 | 2015-03-25 | 中国医学科学院北京协和医院 | 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途 |
| EP3019522B1 (en) | 2013-07-10 | 2017-12-13 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| PT3122775T (pt) * | 2014-03-26 | 2019-12-26 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro |
| CN105646710B (zh) * | 2014-11-17 | 2020-08-25 | 四川科伦博泰生物医药股份有限公司 | 一种全人源化抗vegfr-2单克隆抗体及其制备方法 |
| MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
| CN114796520A (zh) * | 2016-01-27 | 2022-07-29 | 苏特罗生物制药公司 | 抗cd74抗体偶联物，包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法 |
| WO2017180813A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| EP3555627B1 (en) * | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| CN110526991A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN110526979A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109053893B (zh) * | 2018-08-15 | 2021-03-30 | 智享生物(苏州)有限公司 | 一种抗d-二聚体单克隆抗体及其制备方法 |
| CN110882385B (zh) * | 2018-09-07 | 2021-07-09 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CN114341158B (zh) | 2019-07-08 | 2024-08-06 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| CN118406106A (zh) | 2019-07-08 | 2024-07-30 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| WO2021043206A1 (zh) * | 2019-09-03 | 2021-03-11 | 百奥泰生物制药股份有限公司 | 一种抗tigit免疫抑制剂及应用 |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| KR102363980B1 (ko) * | 2020-04-13 | 2022-02-15 | 전남대학교산학협력단 | 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법 |
| WO2021219092A1 (en) * | 2020-04-30 | 2021-11-04 | I-Mab Biopharma Co., Ltd. | Pharmaceutical compositionscontaining anti-cd47 antibodies |
| JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
| CN112540176B (zh) * | 2020-07-08 | 2021-09-28 | 深圳霁因生物医药转化研究院 | 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| IL303925A (en) | 2021-01-07 | 2023-08-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a protein ligand for fibroblast activation and its use |
| WO2023031644A1 (en) | 2021-08-31 | 2023-03-09 | Full-Life Technologies Limited | Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof |
| WO2023125796A1 (en) * | 2021-12-30 | 2023-07-06 | Concept To Medicine Biotech Co., Ltd. | Human antibodies against fap-alpha |
| WO2024027771A1 (zh) * | 2022-08-03 | 2024-02-08 | 南京维立志博生物科技有限公司 | 靶向FAP和TGFβ的抗体融合蛋白及其用途 |
| WO2024074727A1 (en) | 2022-10-07 | 2024-04-11 | Genethon | Immunotherapy of skeletal myopathies using anti-fap car-t cells |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| CN118496382A (zh) * | 2024-05-22 | 2024-08-16 | 山东第一医科大学附属省立医院(山东省立医院) | 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059523A (en) * | 1988-05-02 | 1991-10-22 | Sloan-Kettering Institute For Cancer Research | Cell-surface glycoproteins of human sarcomas |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU2782292A (en) * | 1991-09-18 | 1993-04-27 | Sloan-Kettering Institute For Cancer Research | Activated stromal fibroblast-specific antibody, f19 and methods of using the same |
| ZA936260B (en) * | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
| DK0859841T3 (da) * | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
| IL126121A0 (en) * | 1996-05-01 | 1999-05-09 | Genitope Corp | Vaccines for treatment of lymphoma and leukemia |
-
1998
- 1998-04-30 EP EP98107925A patent/EP0953639A1/en not_active Withdrawn
-
1999
- 1999-04-22 JP JP2000547119A patent/JP4421779B2/ja not_active Expired - Lifetime
- 1999-04-22 TR TR2000/03181T patent/TR200003181T2/xx unknown
- 1999-04-22 AU AU40322/99A patent/AU760305B2/en not_active Ceased
- 1999-04-22 DE DE69935516T patent/DE69935516T2/de not_active Expired - Lifetime
- 1999-04-22 NZ NZ508456A patent/NZ508456A/xx unknown
- 1999-04-22 UA UA2000116786A patent/UA73276C2/uk unknown
- 1999-04-22 BR BR9910577-2A patent/BR9910577A/pt not_active IP Right Cessation
- 1999-04-22 KR KR1020007011585A patent/KR100580936B1/ko not_active IP Right Cessation
- 1999-04-22 YU YU66300A patent/YU66300A/sh unknown
- 1999-04-22 SK SK1619-2000A patent/SK16192000A3/sk unknown
- 1999-04-22 ES ES99923439T patent/ES2283114T3/es not_active Expired - Lifetime
- 1999-04-22 HU HU0101501A patent/HUP0101501A3/hu unknown
- 1999-04-22 PL PL99358087A patent/PL358087A1/xx not_active IP Right Cessation
- 1999-04-22 AT AT99923439T patent/ATE356873T1/de active
- 1999-04-22 ID IDW20002198A patent/ID26555A/id unknown
- 1999-04-22 EE EEP200000642A patent/EE200000642A/xx unknown
- 1999-04-22 IL IL13870199A patent/IL138701A0/xx unknown
- 1999-04-22 WO PCT/EP1999/002711 patent/WO1999057151A2/en not_active Application Discontinuation
- 1999-04-22 EP EP99923439A patent/EP1098979B1/en not_active Expired - Lifetime
- 1999-04-22 EA EA200001023A patent/EA005401B1/ru not_active IP Right Cessation
- 1999-04-22 CN CN99806582A patent/CN1303430A/zh active Pending
- 1999-04-22 CA CA2327586A patent/CA2327586C/en not_active Expired - Lifetime
- 1999-04-29 CO CO99025997A patent/CO5050255A1/es unknown
- 1999-04-30 AR ARP990102015A patent/AR016243A1/es unknown
-
2000
- 2000-10-05 BG BG104828A patent/BG65034B1/bg unknown
- 2000-10-09 ZA ZA200005506A patent/ZA200005506B/en unknown
- 2000-10-27 NO NO20005412A patent/NO20005412L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID26555A (id) | ANTIBODI FAP-α-SPESIFIK DENGAN PERBAIKAN KEMAMPUAN PRODUKSI | |
| DE69920897D1 (de) | Monoklonale antikörper mit verringerter immunisierungsfähigkeit | |
| CY2005008I1 (el) | Αντισωματα αντι - vegf | |
| ID28990A (id) | Herbisida-herbisida dengan urea aminofenilsulfonil asilasi | |
| ID24425A (id) | Produksi alkilaromatik | |
| ATE267257T1 (de) | Humanisierte anti-koerper gegen cd11a | |
| NO20002957L (no) | Behandling med anti-ErbB2-antistoffer | |
| ID16966A (id) | Sediaan antibodi pekat | |
| DE69943250D1 (de) | Fahrzeugherstellung | |
| ID27092A (id) | Pembuatan ftalat anhidrida | |
| ATA33597A (de) | Faktor x-analoge mit modifizierter proteasespaltstelle | |
| DE69826135D1 (de) | Programmerzeugung | |
| EE200300179A (et) | Humaniseeritud LT-ß-R-i vastased antikehad | |
| DK1308455T3 (da) | Sammensætning omfattende anti-HER2-antistoffer | |
| ID27776A (id) | Bahan dengan efek antidepresan | |
| DE69815367D1 (de) | Flachdichtungsherstellung | |
| ID20359A (id) | Produksi dekstran | |
| ID20238A (id) | Produksi l(+)-laktat | |
| DE59905139D1 (de) | Strukturelement | |
| DE69908863D1 (de) | Einspritzventil | |
| ID28905A (id) | Antibodi-antibodi dengan afinitas tinggi | |
| ID27962A (id) | Pembuatan tetrahidrofuran | |
| NO991372D0 (no) | Trinn med reflektorer | |
| DE59911463D1 (de) | Fahrzeugleitvorrichtung mit Fahrstreckenabtastung | |
| ID22488A (id) | Struktur bagian pembakaran dari penyala |